Treating liver fibrosis using adipose stem cell-derived exosomes as active ingredient

• US 11,241,459 B2
• Filed: 11/21/2017
• Issued: 02/08/2022
• Est. Priority Date: 11/21/2016
• Status: Active Grant

• Current Assignee: Exostemtech Co., Ltd.
• Original Assignee: Exostemtech Co., Ltd.
• Inventors: Park, Jae Hyung, Lee, Hansang, Heo, Roun, Han, Hwa Seung
• Primary Examiner(s): Gitomer, Ralph J
• Application Number:
  US16/462,501
• Publication Number:
  US 20190314419A1
• Time in Patent Office: 1,540 Days
• Field of Search: None
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present embodiment relates to a composition containing human adipose stem cell-derived exosomes as an active ingredient for preventing, alleviating or treating liver fibrosis. The adipose stem cell-derived exosomes according to the present embodiment carry genetic information, protein, growth factor and the like for treating liver fibrosis, and have shown excellent results in treating liver fibrosis in animal models therefor, and, being a cell-derived substance, exosomes have the advantages of being highly biocompatible and having a superb absorption rate.

Claims

1. A method for alleviating or treating liver fibrosis, comprising administering a composition comprising adipose stem cell-derived exosomes as an active ingredient to a subject in need thereof.

2. The method according to claim 1,

wherein the adipose stem cell is human adipose stem cell.

3. The method according to claim 1,

wherein the composition reduces a level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TP), or LW/BW (Ratio of liver weight to body weight) in blood.

4. The method according to claim 1,

wherein the composition is a pharmaceutical or a food composition.